hrp0089rfc10.6 | Late Breaking | ESPE2018

Effect of the Current Treatment of X-Linked Hypophosphatemia During Growth on the Development of Osteoarticular Lesions in the Hyp Mouse Model

Cauliez Axelle , Faraji-Bellee Carole-Anne , Salmon Benjamin , Fogel Olivier , Benoit Aurelie , Schinke Thorsten , Miceli Corinne , Briot Karine , Linglart Agnes , Chaussain Catherine , Bardet Claire

Mineralization defects and paradoxical mineralizing enthesopathies are hallmarks of X-linked Hypophosphatemia (XLH), a rare skeletal disease caused by inactivating mutations in the PHEX gene (Phosphate-regulating endopeptidase homolog, X-linked). The current medical treatment, which consist in oral phosphorus supplementation and active vitamin D analogues, aimed at counteracting consequences of FGF23 excess and is commonly prescribed from early childhood to the end of...